Short Interest in Edwards Lifesciences Corporation (NYSE:EW) Increases By 56.6%

Edwards Lifesciences Corporation (NYSE:EW) saw a significant increase in short interest in February. As of February 27th, there was short interest totaling 12,376,285 shares, an increase of 56.6% from the February 12th total of 7,902,820 shares. Approximately 2.1% of the company’s shares are short sold. Based on an average trading volume of 4,625,420 shares, the short-interest ratio is currently 2.7 days. Based on an average trading volume of 4,625,420 shares, the short-interest ratio is currently 2.7 days. Approximately 2.1% of the company’s shares are short sold.

Insider Buying and Selling

In other news, VP Donald E. Bobo, Jr. sold 24,000 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $83.84, for a total value of $2,012,160.00. Following the completion of the transaction, the vice president owned 21,266 shares in the company, valued at approximately $1,782,941.44. The trade was a 53.02% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Scott B. Ullem sold 13,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $84.92, for a total value of $1,103,960.00. Following the transaction, the chief financial officer directly owned 39,699 shares in the company, valued at approximately $3,371,239.08. This represents a 24.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 61,718 shares of company stock worth $5,236,281. Corporate insiders own 0.34% of the company’s stock.

Hedge Funds Weigh In On Edwards Lifesciences

Several institutional investors have recently made changes to their positions in EW. Vanguard Group Inc. raised its holdings in shares of Edwards Lifesciences by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 70,363,210 shares of the medical research company’s stock valued at $5,472,147,000 after purchasing an additional 365,581 shares in the last quarter. State Street Corp lifted its position in shares of Edwards Lifesciences by 1.5% in the 4th quarter. State Street Corp now owns 25,991,524 shares of the medical research company’s stock worth $2,215,777,000 after purchasing an additional 371,892 shares during the period. Wellington Management Group LLP boosted its stake in shares of Edwards Lifesciences by 4.8% during the fourth quarter. Wellington Management Group LLP now owns 21,793,949 shares of the medical research company’s stock valued at $1,857,934,000 after purchasing an additional 989,533 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in Edwards Lifesciences by 8.1% during the third quarter. Bank of New York Mellon Corp now owns 19,010,227 shares of the medical research company’s stock valued at $1,478,425,000 after buying an additional 1,423,365 shares during the period. Finally, Jennison Associates LLC increased its holdings in Edwards Lifesciences by 19.6% during the third quarter. Jennison Associates LLC now owns 13,958,774 shares of the medical research company’s stock valued at $1,085,574,000 after buying an additional 2,287,783 shares during the period. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on EW shares. Truist Financial set a $89.00 target price on shares of Edwards Lifesciences and gave the company a “hold” rating in a research note on Wednesday, February 11th. Evercore reaffirmed an “outperform” rating and set a $94.00 price target on shares of Edwards Lifesciences in a research note on Monday, January 5th. UBS Group reiterated a “neutral” rating and set a $94.00 price target on shares of Edwards Lifesciences in a report on Wednesday, February 4th. Royal Bank Of Canada increased their price objective on shares of Edwards Lifesciences from $95.00 to $100.00 and gave the stock an “outperform” rating in a research report on Friday, December 5th. Finally, Barclays reissued an “overweight” rating and issued a $104.00 price objective (up from $103.00) on shares of Edwards Lifesciences in a research note on Monday, January 12th. Three analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $96.14.

Edwards Lifesciences Trading Down 3.3%

EW stock traded down $2.79 during trading on Friday, hitting $81.82. The company had a trading volume of 5,617,686 shares, compared to its average volume of 4,610,997. Edwards Lifesciences has a 52-week low of $65.94 and a 52-week high of $87.89. The company has a 50 day simple moving average of $82.41 and a 200-day simple moving average of $81.58. The firm has a market capitalization of $47.52 billion, a P/E ratio of 44.71, a PEG ratio of 2.13 and a beta of 0.93. The company has a quick ratio of 3.09, a current ratio of 3.72 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Tuesday, February 10th. The medical research company reported $0.58 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.62 by ($0.04). Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The company had revenue of $1.57 billion during the quarter, compared to analysts’ expectations of $1.54 billion. During the same period last year, the firm earned $0.59 earnings per share. Edwards Lifesciences’s quarterly revenue was up 13.3% on a year-over-year basis. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. As a group, research analysts forecast that Edwards Lifesciences will post 2.45 earnings per share for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.